IP Library Granted Patent US 9,107,947
Granted Patent B2
US 9,107,947 · App. 14/169,639 · Granted Aug 18, 2015

Anti-cancer compositions and methods

Inventors: Gavin P. Robertson (Hummelstown, PA); Chandagalu D. Raghavendra Gowda (Hershey, PA); Dhimant H. Desai (Mechanicsburg, PA); Shantu G. Amin (Union City, NJ)
Assignee: The Penn State Research Foundation
A61K45/06A61K9/1271A61K31/415A61K31/095C07D231/10C07D231/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,107,947
App. No.
14/169,639
Granted
Aug 18, 2015
Kind
B2
Abstract

Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.

Claims (10)

1. A composition comprising

a selenium-containing COX-2 inhibitor, wherein the selenium-containing COX-2 inhibitor is selenocoxib-1-glutathione (selenocoxib-1-GSH).

2. A pharmaceutical composition, comprising:

a selenium-containing COX-2 inhibitor, wherein the selenium-containing COX-2 inhibitor is selenocoxib-1-GSH; and

a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated for topical application.

4. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises a particulate carrier.

5. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises a nanoparticulate carrier.

6. The pharmaceutical composition of claim 2 , comprising a plurality of nanoliposomes, the nanoliposomes comprising selenocoxib-1-GSH, the nanoliposomes having an average particle size in the range of 1-100 nm.

7. The pharmaceutical composition of claim 2 , further comprising an additional therapeutic agent.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 26, 2014
From: THE PENNSYLVANIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033832/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2014
From: ROBERTSON, GAVIN P.; RAGHAVENDRA GOWDA, CHANDAGALU D.; DESAI, DHIMANT H.; AMIN, SHANTU G.
To: THE PENN STATE RESEARCH FOUNDATION
Reel/Frame 032121/0015 →
Continuity (2)
Provisional Application 61759034 · Jan 31, 2013
Related Publication 20140212475A1 · Jul 31, 2014